The European Commission has granted authorisations for 11 uses of 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (review period expiry dates in brackets):

• 1 use by Vetter Pharma-Fertigung GmbH & Co. KG (4 January 2026);
• 1 use by Nuova Ompi S.r.l. Unipersonale (4 January 2026);
• 1 use by Abbott Diagnostics GmbH (4 January 2028);
• 1 use by Ortho-Clinical Diagnostics France (4 January 2031);
• 1 use by Novo Nordisk A/S (4 January 2033);
• 2 uses by BioMarin International Limited (4 January 2033);
• 2 uses by Janssen Vaccines & Prevention B.V. and Janssen Biologics B.V. (4 January 2033); and
• 2 uses by Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim RCV GmbH & Co KG (4 January 2033).

The Commission has also granted an authorisation for one use of chromium trioxide by ThyssenKrupp Electrical Steel GmbH & Thyssenkrupp Electrical Steel UGO S.A.S. (31 December 2029).